Fibrosis/Cancer Start-up Seeded By Celgene Begins To Take Shape
This article was originally published in The Pink Sheet Daily
Executive Summary
Bay City Capital will back the PharmAkea with a $10 million Series A financing. Celgene also holds an undisclosed equity stake in the new company, under a three-year, $35 million R&D funding agreement with options to extend the arrangement or acquire the firm.
You may also be interested in...
The A-List: The Trend-Shaping Series A Financings Of 2013
It’s the 10th anniversary of START-UP’s A-List, an analysis of the year’s Series A life science funding, and a highlight of the year’s most interesting new companies. Deal flow was up this year, as was the average disclosed amount of financing.
For Its Latest Epigenetics Deal, Celgene Takes Option To Buy Acetylon
A $100 million, non-dilutive investment will keep Acetylon off the market, giving Celgene the right to buy it for a minimum of $500 million up-front within a pre-determined time window. For now, Acetylon retains all rights to its pipeline, including Phase Ib multiple myeloma drug ACY-1215.
BMS Bets On Amira's IPF Drug In $325M Acquisition
The deal expands BMS's inflammatory disease holdings while bringing double-digit returns to the six-year-old startup's earliest investors.